{"disease":{"id":"solid-tumors-refractory-to-standard-therapy","name":"solid tumors refractory to standard therapy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01014936","title":"First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":149,"lead_sponsor_name":"EMD Serono","has_results":true},{"nct_id":"NCT06940349","title":"Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Rabin Medical Center","has_results":false},{"nct_id":"NCT06911333","title":"AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Avelos Therapeutics Inc.","has_results":false},{"nct_id":"NCT06883539","title":"A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"LaunXP Biomedical Co., Ltd.","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}